Mode
Text Size
Log in / Sign up
N/A N=32 Treatment

Activating and Connecting Teens (ACT) Study

Depression

Enrolled (actual)
32
Serious AEs
0.0%
Results posted
May 2024
Primary outcome: Primary: Depression — 9.63 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Behavioral Activation (Behavioral)
Age
Pediatric, Adult · 12+ yrs
Sex
All
Sponsor
University of Washington
Primary completion
Mar 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Depression
9.63
PRIMARY
Anhedonia/Activation
61.80

Summary

National data indicate over 650,000 children and adolescents are exposed to physical, sexual, or emotional abuse or physical or emotional neglect each year. Moreover, youth with a history of childhood maltreatment (CM) are at least twice as likely to develop depression and are at substantial risk for nonresponse to current best practice depression interventions (i.e., cognitive behavioral therapy and antidepressants) compared to non-maltreated peers. Research suggests that CM increases risk for depression through disruptions in the positive valence system, such as reward processing, and Behavioral Activation (BA) may be an alternative depression intervention that targets these deficits. This proposal will examine whether BA intervention reduces depression and anhedonia in a sample of depressed adolescents, aged 13-18, with variable histories of CM exposure (BA Group). A total of 30 depressed adolescents will be recruited to undergo a 12-week course of BA. All participants will undergo clinical assessment to measure depression symptoms and anhedonia at baseline (Week 0) and post- (Week 12) treatment.

Eligibility Criteria

Inclusion Criteria Behavioral Activation Group:

  • current diagnosis of clinical depression (minor or major) will be recruited as study participants in the Behavioral Activation (BA) Group

Exclusion Criteria

  • IQ < 80;
  • non-English speaking youth or parent;
  • current PTSD diagnosis;
  • lifetime history of a developmental (e.g., autism), neurological (e.g., epilepsy), psychotic, bipolar, or substance disorder;
  • current psychiatric (e.g., antidepressants) or other mood altering medication (e.g., steroids) other than AD/HD medication;
  • requiring a higher level of care (i.e., inpatient hospitalization) due to suicidality or other mental or physical health related problem.
  • Any youths who are currently being maltreated will not be enrolled to ensure that participants do not have active safety concerns.
  • Full course of other evidence-based depression intervention
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03438656). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search